사단법인 대한부인종양연구회 (KGOG)
notice. KGOG 2025 캠페인 희망 더하기, 부인암 연구기금 마련 걷기대회. more
Korean Gynecologic Oncology Group - KGOG
Bureau of the Korean Gynecologic Oncology Group 2-ho, 2nd Floor, 32, Nambusunhwan-ro 333-gil, Seocho-gu, Seoul 06725, Korea
A single-arm, phase II study of niraparib and bevacizumab …
Dec 6, 2021 · Methods. The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited …
From the Beginning of the Korean Gynecologic Oncology Group …
2.3. Interaction with Other International Research Organizations. Since its establishment, the KGOG has collaborated with prominent international institutions leading multi-center research, …
The 1st annual meeting of the East Asian Gynecologic Oncology …
INTRODUCTION. On November 19, 2021, 4 clinical trial groups, the Japanese Gynecologic Oncology Group (JGOG), the Korean Gynecologic Oncology Group (KGOG), the Taiwanese …
A single-arm, phase II study of niraparib and bevacizumab
ClinicalTrials.gov Identifier: NCT04734665. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients …
A phase II study of neoadjuvant chemotherapy plus durvalumab and ...
Background: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We …
Korean Gynecologic Oncology Group - KGOG
Chairman: Professor Ki-dong Kim 06.01. The 1 st JGOG-KGOG Web Meeting-Cervical Cancer Committee (Webmeeting) . 07.13. The 2 nd JGOG-KGOG Web Meeting-Ovary Cancer …
756P Final analysis of KGOG3046/TRU-D: A phase II study of …
In the original cohort (O) of KGOG 3046 study (NCT03899610) on newly diagnosed advanced-stage epithelial ovarian cancer (aEOC), patients receiving neoadjuvant chemotherapy (NAC) …
Neoadjuvant Durvalumab Plus Tremelimumab Combo Elicits …
Apr 14, 2022 · Initial data from the phase 2 KGOG 3046 trial (NCT03899610) that were presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting demonstrated …